• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

Health Authority Contracted Accelero for SARS-CoV-2 Testing

One of Berlin´s health authorities (Gesundheitsamt Treptow-Köpenick) has signed a contract for Accelero´s SARS-CoV-2 RT-PCR testing capabilities. The Berlin Senate Administration for Health asked Accelero to purchase swaps in bulk.

According to §24 and §47 section 4 Infection Protection Act (Infektionsschutzgesetz, IfSG), the medical diagnosis is subject to the doctor's reservation. Accelero will therefore always provide such services under the supervision or on behalf of a medical officer who is authorized for handling human pathogens according to §44 IfSG. We are quite aware that the German medical diagnostics lobby tries to communicate something different in the media, and claims all diagnostic testing for themselves. However, as long as you work in line with the Infection Protection Act, small lab service providers like Accelero indeed are in the position to provide diagnostic testing as well.

Actually Accelero tests 10 - 40 swap samples per day. The health authority plans to collaborate with Accelero over a time period of seven months. Integral part of the contract is the provision of appropriate wet swaps for sample collection.

Accelero has been asked from time to time whether the lab has experience with the quantification of RNA-based virus particles in different biological matrices. A high throughput sample processing in combination with RT-PCR testing is especially required when it comes to regulatory biodistribution studies e.g. for exploring virus-like particles as a putative vaccine in a ferret model. With the SARS-CoV-2 testing activities ahead, we now believe such kind of question has become obsolete for Accelero clients :)